

## Product datasheet for **TR314349**

### **C1ORF190 (LURAP1) Human shRNA Plasmid Kit (Locus ID 541468)**

#### **Product data:**

<b>Product Type:</b>	shRNA Plasmids
<b>Product Name:</b>	C1ORF190 (LURAP1) Human shRNA Plasmid Kit (Locus ID 541468)
<b>Locus ID:</b>	541468
<b>Synonyms:</b>	C1orf190; LRAP35a; LRP35A
<b>Vector:</b>	pRS (TR20003)
<b>E. coli Selection:</b>	Ampicillin
<b>Mammalian Cell Selection:</b>	Puromycin
<b>Format:</b>	Retroviral plasmids
<b>Components:</b>	LURAP1 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID = 541468). 5µg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free.
<b>RefSeq:</b>	<a href="#">BC034422</a> , <a href="#">NM_001013615</a> , <a href="#">NM_001013615.1</a> , <a href="#">NM_001013615.2</a> , <a href="#">BC034422.1</a> , <a href="#">NM_001013615.3</a>
<b>UniProt ID:</b>	<a href="#">Q96LR2</a>
<b>Summary:</b>	Acts as an activator of the canonical NF-kappa-B pathway and drive the production of proinflammatory cytokines. Promotes the antigen (Ag)-presenting and priming function of dendritic cells via the canonical NF-kappa-B pathway (PubMed:21048106). In concert with MYO18A and CDC42BPA/CDC42BPB, is involved in modulating lamellar actomyosin retrograde flow that is crucial to cell protrusion and migration. Activates CDC42BPA/CDC42BPB and targets it to actomyosin through its interaction with MYO18A, leading to MYL9/MLC2 phosphorylation and MYH9/MYH10-dependent actomyosin assembly in the lamella (By similarity).[UniProtKB/Swiss-Prot Function]
<b>shRNA Design:</b>	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact <a href="mailto:techsupport@origene.com">techsupport@origene.com</a> . If you need a special design or shRNA sequence, please utilize our <a href="#">custom shRNA service</a> .



[View online »](#)

**Performance  
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at [techsupport@origene.com](mailto:techsupport@origene.com). Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).